Literature DB >> 1550701

The importance of general practitioner information in selection of volunteers for clinical trials.

N Watson1, P J Wyld.   

Abstract

The safe conduct of phase I volunteer studies requires careful selection and screening of volunteers. We have reviewed the results of the selection procedure in our clinic. The information received from the volunteer's general practitioner revealed clinical problems which had not been disclosed during medical history or examination.

Mesh：

Year:  1992        PMID： 1550701      PMCID： PMC1381309          DOI： 10.1111/j.1365-2125.1992.tb04026.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  1 in total

1.  The selection of healthy volunteers for clinical investigation: the case for volunteer pools.

Authors:  P Joubert; P Pannall
Journal:  Curr Med Res Opin       Date:  1976       Impact factor: 2.580
  1 in total
  4 in total

1.  The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research.

Authors:  S D Singh; A J Williams
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Safety, Science, or Both? Deceptive Healthy Volunteers: Psychiatric Conditions Uncovered by Objective Methods of Screening.

Authors:  Adriana Pavletic; Maryland Pao
Journal:  Psychosomatics       Date:  2017-05-09       Impact factor: 2.386

3.  Analysis of ehealth search perspectives among female college students in the health professions using Q methodology.

Authors:  Michael Stellefson; Bruce Hanik; J Don Chaney; Bethany Tennant
Journal:  J Med Internet Res       Date:  2012-04-27       Impact factor: 5.428

4.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.